伴侣动物药品市场规模、份额和成长分析（按产品、动物种类、给药途径、通路和地区划分）－2025-2032年产业预测

预计到 2023 年，全球伴侣动物药品市场规模将达到 159 亿美元，到 2024 年将达到 172 亿美元，到 2032 年将达到 323.2 亿美元，预测期（2025-2032 年）的复合年增长率为 8.2%。

全球伴侣动物药品市场呈现稳定成长态势，主要受宠物饲养率上升和宠物健康领域投资增加的推动，而这又主要源自于人们对宠物福利意识的不断提高。犬猫作为最常见的伴侣动物，抗感染剂、疫苗、疼痛管理药物和皮肤病治疗产品的需求尤其显着。兽医诊断和药物传输技术的创新，以及个人化宠物医疗的发展，正在推动市场动态。关节炎、糖尿病和肥胖等慢性疾病发病率的上升，使得长期治疗方案的需求日益增长，从而刺激了市场需求。宠物人性化趋势，尤其是在北美和欧洲，正在促进研发和新产品开发。此外，兽医远距医疗和网路药局服务的扩展，正在改善宠物获得治疗的机会，尤其是在服务不足的地区。同时，由于经济发展和兽医保健服务的改善，亚太和拉丁美洲市场正经历快速成长。

全球伴侣动物药品市场驱动因素

全球伴侣动物药品市场的主要驱动力是人们对宠物饲养的认知和接受度不断提高，这推动了对兽医保健产品和服务的需求。随着越来越多的家庭将宠物视为家庭成员，人们对宠物的整体健康和福祉也日益关注。这一趋势的驱动因素包括可支配收入的增长、都市化的加快以及人们对高端宠物护理服务的追求，这些因素促使宠物饲主在预防性护理、慢性病管理和专科药物方面进行投资。此外，兽医学的进步和宠物保险的日益普及也进一步推动了该市场的成长。

全球伴侣动物药品市场阻碍因素

全球伴侣动物药品市场的主要限制因素之一是兽药核准和商业化过程中严格的法规环境。製药公司在应对复杂的核准流程方面面临巨大挑战，该流程要求进行广泛的临床试验和安全性评估，以确保产品对动物和人类的有效性和安全性。这会导致新产品研发成本增加，上市时间延长。此外，区域监管差异也会阻碍公司拓展国际产品线，进一步增加市场进入和成长策略的复杂性。

全球伴侣动物医药市场趋势

随着宠物越来越被拟人化，全球伴侣动物药品市场对高品质治疗药物的需求显着增长。这种转变推动了对符合人类标准的医疗保健解决方案的需求，包括文明病治疗、心理健康护理和疼痛管理。由于宠物饲主越来越重视宠物的健康和福祉，处方药的需求也大幅增加，其中包括长效注射和抗焦虑药物。这一趋势在都市区市场尤其明显，宠物饲主热衷于投资先进的医疗保健方案，以提升伴侣动物的生活品质。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

伴侣动物药品市场规模（依产品划分）及复合年增长率（2025-2032 年）

• 市场概览
• 製药
  • 抗寄生虫药物
  • 抗发炎药
  • 抗感染剂
  • 皮质类固醇
  • 镇静剂
  • 循环系统药物
  • 消化器官系统药物
• 疫苗
  • 活病毒疫苗）
  • 灭活疫苗
  • 重组疫苗
• 药用饲料添加剂
  • 抗生素
  • 维他命
  • 胺基酸
  • 酵素
  • 抗氧化剂
  • 益生元和益生菌
  • 矿物
  • 碳水化合物
  • 丙二醇

伴侣动物药品市场规模（以动物类型划分）及复合年增长率（2025-2032 年）

• 市场概览
• 狗
• 猫
• 马
• 其他动物物种

伴侣动物药品市场规模（依给药途径及复合年增长率划分）（2025-2032 年）

• 市场概览
• 口服
• 注射
• 外用
• 其他给药途径

伴侣动物药品市场规模（依通路划分）及复合年增长率（2025-2032 年）

• 市场概览
• 兽医院药房
• 电子商务
• 零售药房

伴侣动物药品市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• Zoetis Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Merck & Co., Inc.（United States）
• Elanco Animal Health Incorporated（United States）
• IDEXX Laboratories, Inc.（United States）
• Virbac SA（France）
• Ceva Sante Animale SA（France）
• Dechra Pharmaceuticals PLC（United Kingdom）
• Vetoquinol SA（France）
• Phibro Animal Health Corporation（United States）
• Bayer AG（Germany）
• Norbrook Laboratories（United Kingdom）
• Krka, dd, Novo mesto（Slovenia）
• Intas Pharmaceuticals（India）
• Hester Biosciences Ltd.（India）
• Zydus Animal Health（India）
• Abbott Laboratories（United States）
• IDT Biologika（Germany）
• Bimeda（Ireland）
• Neogen Corporation（United States）

结论与建议

Global Companion Animal Pharmaceuticals Market size was valued at USD 15.9 billion in 2023 and is poised to grow from USD 17.2 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The global companion animal pharmaceuticals market demonstrates consistent growth, propelled by rising pet adoption rates and heightened investment in pet health, largely due to increasing awareness of animal welfare. A surge in demand for anti-infectives, anti-parasitics, vaccines, pain management, and dermatological products is particularly evident for dogs and cats, prominent as companion animals. Innovations in veterinary diagnostics and drug delivery, along with personalized medicine for pets, are enhancing market dynamics. The growing incidence of chronic diseases like arthritis, diabetes, and obesity necessitates long-term therapeutic approaches, thus boosting demand. Trends toward pet humanization, especially in North America and Europe, stimulate R&D and new product formulations. Additionally, the expansion of veterinary telemedicine and e-pharmacy services is enhancing treatment accessibility, particularly in underserved regions, while Asia-Pacific and Latin America experience rapid growth due to economic progress and improved veterinary services.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Companion Animal Pharmaceuticals Market Segments Analysis

Global Companion Animal Pharmaceuticals Market is segmented by Product, Animal Type, Route of Administration, Distribution Channel and region. Based on Product, the market is segmented into Drugs, Vaccines and Medicated feed additives. Based on Animal Type, the market is segmented into Dogs, Cats, Horses and Other animal types. Based on Route of Administration, the market is segmented into Oral, Injectable, Topical and Other routes of administration. Based on Distribution Channel, the market is segmented into Veterinary hospital pharmacies, E-commerce and Retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Companion Animal Pharmaceuticals Market

A key market driver for the Global Companion Animal Pharmaceuticals Market is the increasing awareness and acceptance of pet ownership, which has led to a growing demand for veterinary healthcare products and services. As more households consider pets as family members, there is a heightened emphasis on their overall health and well-being. This trend is catalyzed by rising disposable incomes, urbanization, and a shift towards premium pet care services, prompting pet owners to invest in preventive care, chronic disease management, and specialty pharmaceuticals. Additionally, advancements in veterinary medicine and an increase in pet insurance coverage further bolster this market's growth.

Restraints in the Global Companion Animal Pharmaceuticals Market

One key market restraint for the global companion animal pharmaceuticals market is the stringent regulatory environment governing the approval and commercialization of veterinary drugs. Pharmaceutical companies face significant challenges in navigating complex approval processes that require extensive clinical trials and safety evaluations to ensure product efficacy and safety for both animals and humans. This can lead to increased development costs and extended timelines for bringing new products to market. Additionally, the variability in regulations across different regions can create barriers for companies looking to expand their product offerings internationally, further complicating market entry and growth strategies.

Market Trends of the Global Companion Animal Pharmaceuticals Market

The Global Companion Animal Pharmaceuticals market is experiencing a notable trend towards premium therapeutics, fueled by the increasing humanization of pets. This shift has led to a heightened demand for healthcare solutions that parallel human standards, encompassing treatments for lifestyle diseases, mental wellness, and pain management. As pet owners prioritize their animals' health and well-being, there is a significant expansion in prescription therapeutics, including long-acting injectables and anti-anxiety medications. This trend is particularly pronounced in urban markets, where pet owners are more likely to invest in advanced healthcare options that promote optimal quality of life for their companions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Companion Animal Pharmaceuticals Market Size by Product & CAGR (2025-2032)

• Market Overview
• Drugs
  • Antiparasitic
  • Anti-inflammatory
  • Anti-infectives
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
• Vaccines
  • Modified live vaccines (MLV)
  • Killed inactivated vaccines
  • Recombinant vaccines
• Medicated feed additives
  • Antibiotics
  • Vitamins
  • Amino acids
  • Enzymes
  • Antioxidants
  • Prebiotics and probiotics
  • Minerals
  • Carbohydrates
  • Propanediol

Global Companion Animal Pharmaceuticals Market Size by Animal Type & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Horses
• Other animal types

Global Companion Animal Pharmaceuticals Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical
• Other routes of administration

Global Companion Animal Pharmaceuticals Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies

Global Companion Animal Pharmaceuticals Market Size & CAGR (2025-2032)

• North America (Product, Animal Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Product, Animal Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Animal Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Animal Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Animal Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norbrook Laboratories (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d., Novo mesto (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Animal Health (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bimeda (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neogen Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations